Navigation Links
Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
Date:8/4/2008

the potential inability to reach final agreement with regulatory agencies on the use of a surrogate endpoint and phase 3 trial design for Amigal, the potential that results of clinical or pre-clinical studies indicate that the product candidates are unsafe or ineffective; and, our dependence on third parties in the conduct of our clinical studies; further, the results of earlier clinical trials may not be predictive of future results; and other risks detailed in our annual Report on Form 10-K for the year ended December 31, 2007, and our other public filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Amicus undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.


'/>"/>
SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
2. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
3. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
4. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
5. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
6. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
7. Nile Therapeutics Announces Dosing in Second Phase Ib Study of CD-NP in Heart Failure Patients
8. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
9. Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
10. Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters
11. Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinsons Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... April 24, 2015  Lannett Company, Inc. (NYSE: ... increased its five-year revolving credit facility to $120 million ... feature that will allow the company to increase borrowings ... million, subject to securing additional commitments from existing lenders ... credit facility remains December 18, 2018.   ...
(Date:4/24/2015)... Spain , April 24, 2015  Elekta has ... Monaco® treatment planning system , enabling European clinics ... supports major treatment techniques including advanced 3D planning, IMRT, ... system. Monaco ... as well improved workflow efficiency. Advancements in 3D planning ...
(Date:4/23/2015)...  Edwards Lifesciences Corporation (NYSE: EW ), the ... hemodynamic monitoring, today reported net income for the quarter ... diluted share.  Net income for the same period a ... share, and non-GAAP net income was $82.1 million, or ... the quarter ended March 31, 2015 increased 13.0 percent to ...
Breaking Medicine Technology:Lannett Expands Revolving Credit Facility To $120 Million 2Elekta CE marks for Monaco v5.10 treatment planning system 2Edwards Lifesciences Reports First Quarter Results 2Edwards Lifesciences Reports First Quarter Results 3Edwards Lifesciences Reports First Quarter Results 4Edwards Lifesciences Reports First Quarter Results 5Edwards Lifesciences Reports First Quarter Results 6Edwards Lifesciences Reports First Quarter Results 7Edwards Lifesciences Reports First Quarter Results 8Edwards Lifesciences Reports First Quarter Results 9Edwards Lifesciences Reports First Quarter Results 10Edwards Lifesciences Reports First Quarter Results 11Edwards Lifesciences Reports First Quarter Results 12Edwards Lifesciences Reports First Quarter Results 13Edwards Lifesciences Reports First Quarter Results 14Edwards Lifesciences Reports First Quarter Results 15Edwards Lifesciences Reports First Quarter Results 16
... 2 Results from studies related ... ) lead developmental product candidate, fidaxomicin, ... Annual Interscience Conference on Antimicrobial Agents and Chemotherapy ... and Exhibition Center in Boston on September 12-15, ...
... Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins... -- DALLAS, Texas, September 2, 2010 ... ... (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we need ...
Cached Medicine Technology:Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting 2Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting 3Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies Now Available at ReportsandReports 2Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies Now Available at ReportsandReports 3Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies Now Available at ReportsandReports 4Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies Now Available at ReportsandReports 5Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies Now Available at ReportsandReports 6Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies Now Available at ReportsandReports 7Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies Now Available at ReportsandReports 8
(Date:4/25/2015)... Caicos Islands, BWI (PRWEB) April 25, 2015 ... (PLS) has celebrated three months of successfully welcoming visitors ... January 5, 2015. , As part of a ... of Providenciales airport was completely redesigned to speed up ... up the process of getting out of the airport ...
(Date:4/25/2015)... On Friday, April 17, Interstate Batteries ... Best Implementation Award. This award is given to ... of RFID technology to improve its manufacturing, supply chain ... best demonstrates how RFID is delivering real value to ... Live! 2015 in San Diego, the RFID industries annual ...
(Date:4/24/2015)... As the nation recognizes the Month ... of these young men and women, the “Alaska – ... their Families” presents a special training session on Adverse ... a better understanding of the effect of childhood trauma ... – civilian and military – who provide services and ...
(Date:4/24/2015)... The 1975 have had an intense past two ... theaters, festivals and TV performances. Now that they’ve settled back ... Dirty Hit Records, to provide clean drinking water to those ... Cadence & Cause website, this four-piece has graciously donated ... signed photo card. Entries from this sweepstakes will ...
(Date:4/24/2015)... 2015 Anchor Health Administrators (Anchor), specialists ... today announced their exclusive agreement with LTC Solutions for ... Insurance distribution partner. , Anchor has more than 18 ... benefits for associations, and is currently the designated advocate ... Term Care Insurance member benefit. , “I am very ...
Breaking Medicine News(10 mins):Health News:The Tuscany on Grace Bay Celebrates Providenciales Airport Expansion With Summer Specials to Travelers! 2Health News:Seeonic’s Industry Leading Technology Powers Interstate Batteries to Winning Award 2Health News:Coalition Presents Resiliency Training to Raise Awareness during Month of the Military Child (#MOTMC2015) 2Health News:Internationally Recognized British Indie Rock Outfit The 1975 Partner with Cadence & Cause to Provide Clean Drinking Water to Those in Need 2
... In response to ... In Health (PIH) Stand with Haiti initiative. Buildium started the campaign with a $1,000 donation, ... ... ongoing needs in Haiti, Buildium today announced a fundraising campaign to benefit the Partners In ...
... , ... ... ... ...
... , ... ... , ... , , ...
... deal with physical pain, researchers say , THURSDAY, Feb. ... back pain may find relief through cognitive behavioral therapy, ... beliefs. , Chronic lower back pain is one of ... the British researchers report. And, it can be expensive ...
... , ... ... , , , ... ...
... drugs intended to halt growth of brain cancer stem cells ... conclude that blocking these cells may be somewhat effective, but ... the job done. One focus of attack is a ... shown is important for cancer stem cell growth. A new ...
Cached Medicine News:Health News:Buildium Announces Fundraising Campaign to Benefit Haiti Relief Efforts 2Health News:DNC Chairman Tim Kaine Applauds President, Members of Congress on Today's Bipartisan Summit 2Health News:DNC Chairman Tim Kaine Applauds President, Members of Congress on Today's Bipartisan Summit 3Health News:Clinton Bush Haiti Fund Awards International Medical Corps $500,000 for Emergency Medical Care and Long-Term Rebuilding 2Health News:Clinton Bush Haiti Fund Awards International Medical Corps $500,000 for Emergency Medical Care and Long-Term Rebuilding 3Health News:Chronic Back Pain Soothed by Cognitive Behavioral Therapy 2Health News:Chronic Back Pain Soothed by Cognitive Behavioral Therapy 3Health News:NSBA Implores Congress to Act on Health Care Reform 2Health News:NSBA Implores Congress to Act on Health Care Reform 3Health News:Notch-blocking drugs kill brain cancer stem cells, yet multiple therapies may be needed 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: